A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer

Author： Margolin Sara   Bengtsson Nils-Olof   Carlsson Lena   Edlund Per   Hellstrøm Mats   Karlsson Per   Lidbrink Elisabet   Linderholm Barbro   Lindman Henrik   Malmström Per   Pettersson Skøld Dagny   Søderberg Martin   Villman Kenneth   Bergh Jonas    

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.50, Iss.1, 2011-01, pp. : 35-41

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer

By Cooper Brenda   Radivoyevitch Tomas   Overmoyer Beth   Shenk Robert   Pham Huong   Samuels Judith   Parry Margaret   Silverman Paula  

Breast Cancer Research and Treatment, Vol. 97, Iss. 3, 2006-06 ,pp. : 311-318

Springer Publishing Company

Access to resources Recommend Favorite

Primary systemic chemotherapy with sequential, dose-dense epirubicin and docetaxel for inoperable, locally advanced inflammatory breast cancer: A phase II study

By Kümmel Sherko   Thomas Anke   Paepke Stefan   Schwarz Marion   Heinrich Georg   Wetzel Andrea   Elling Dirk   Kohls Andreas   Lichtenegger Werner   Blohmer Jens-Uwe  

Acta Oncologica, Vol. 44, Iss. 3, 2005-05 ,pp. : 248-254

Informa Healthcare

Access to resources Recommend Favorite

Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy

By Lalisang R.   Erdkamp F.   Rodenburg C.   Knibbeler-van Rossum C.   Nortier J.   Bochove A.   Slee P.   Voest E.   Wils J.   Wals J.   Loosveld O.   Smals A.   Blijham G.   Tjan-Heijnen V.   Schouten H.  

Breast Cancer Research and Treatment, Vol. 128, Iss. 2, 2011-07 ,pp. : 437-445

Springer Publishing Company

Access to resources Recommend Favorite

A Phase I Toxicity and Feasibility Trial of Sequential Dose-Dense Induction Chemotherapy with Doxorubicin, Paclitaxel, and 5-Fluorouracil Followed by High Dose Consolidation for High-Risk Primary Breast Cancer

By Emens L.A.   Kennedy M.J.   Fetting J.H.   Davidson N.E.   Garrett E.   Armstrong D.K.  

Breast Cancer Research and Treatment, Vol. 76, Iss. 2, 2002-11 ,pp. : 145-156

Springer Publishing Company

Access to resources Recommend Favorite

Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer

By Fountzilas George   Pectasides Dimitrios   Christodoulou Christos   Timotheadou Eleni   Economopoulos Theofanis   Papakostas Pavlos   Papadimitriou Christos   Gogas Helen   Efstratiou Ioannis   Skarlos Dimosthenis  

Medical Oncology, Vol. 23, Iss. 4, 2006-12 ,pp. : 479-488

Humana Press, Inc

Access to resources Recommend Favorite